Unilin CR Tablet (Controlled Release) 300 mg

Unilin CR Tablet (Controlled Release) is a bronchodilator medication manufactured by Opsonin Pharma Ltd, containing 300 mg of Theophylline. Designed for prolonged action, this controlled-release tablet helps manage respiratory conditions like asthma and COPD by relaxing airway muscles and reducing inflammation.

Priced at ৳2.36 per tablet, Unilin CR offers cost-effective treatment with a strip price of ৳23.60 and pack size of 10×10 tablets for ৳236.00. Its controlled-release formulation ensures sustained therapeutic effects, minimizing frequent dosing while maintaining optimal drug levels in the bloodstream.

Clinically, Unilin CR treats chronic asthma, nocturnal symptoms, COPD, and apnea in premature infants. Theophylline’s dual action suppresses airway hyperactivity and enhances diaphragm muscle function. Dosage varies by age, ranging from 10 mg/kg/day for adults (max 900 mg/day) to 24 mg/kg/day for children aged 1-8 years.

Potential drug interactions include reduced efficacy with barbiturates or rifampicin and increased toxicity with cimetidine or erythromycin. Common side effects like nausea or insomnia are rare at prescribed doses. Store in cool, dry places away from light and children.

Consult doctors before use during pregnancy or breastfeeding. Regular serum monitoring prevents toxicity. Explore alternative Theophylline brands like Unilin 120 mg/5 ml for customized treatment plans under medical supervision.

Adults: 10 mg/kg/day (max 900 mg) every 12 hours. Pediatric dosing adjusted by age: 16 mg/kg/day for 9-11 years. Therapeutic drug monitoring mandatory. Dose adjustments required with hepatic impairment or interacting medications.

Generally side effects are rare at normal dosage. It may include gastrointestinal discomfort, headache, nausea, insomnia and hypotension. CNS stimulation and diuresis may also occur, especially in children.

Pregnancy Category C: Use only if benefits outweigh risks. Excreted in breast milk – may cause infant irritability.

Monitor ECG in cardiac patients. Adjust dose for smokers. Initiate low dose, gradual titration. Opsonin Pharma Ltd recommends therapeutic monitoring.

Neonates require 30% lower doses. Geriatric/hepatic impairment: Reduce dose by 25-50%. Renal adjustment usually unnecessary.